LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 9 of total 9

Search options

  1. Article ; Online: Eradicating hepatitis B virus: The critical role of preventing perinatal transmission.

    Stevens, Cladd E / Toy, Pearl / Kamili, Saleem / Taylor, Patricia E / Tong, Myron J / Xia, Guo-Liang / Vyas, Girish N

    Biologicals : journal of the International Association of Biological Standardization

    2017  Volume 50, Page(s) 3–19

    Abstract: Prevention of hepatitis B virus (HBV) transmission from infected mothers to their newborns is critical to HBV control and eventual eradication. Mother-to-child perinatal transmission causes the highest chronic carrier rate (>85%) with a high rate of ... ...

    Abstract Prevention of hepatitis B virus (HBV) transmission from infected mothers to their newborns is critical to HBV control and eventual eradication. Mother-to-child perinatal transmission causes the highest chronic carrier rate (>85%) with a high rate of subsequent chronic liver disease and hepatocellular carcinoma. This risk is reduced by 90% with HBV vaccine given along with hepatitis B immune globulin (HBIG) starting at birth. New analyses of our data from US trials of HBIG and HBV vaccine in high-risk infants revealed better efficacy with yeast-recombinant vaccine than plasma-derived vaccine, especially in preventing late onset infections, with evidence that vaccine prevented transmission of maternal HBV infection with the glycine to arginine mutation in surface antigen codon 145 (sG145R). Most late infections with sG145R were in vaccine non-responders, suggesting escape from HBIG rather than from vaccine-induced antibody. Our findings also help explain survey results from Taiwan following universal childhood immunization implemented in the mid-1980s. We conclude that current vaccines will remain effective against surface antigen mutants. Anti-viral drugs in high-risk pregnant women, in combination with newborn HBIG and vaccine, show promise for eliminating residual breakthrough neonatal infections, critical to meeting WHO 2030 goals and for eradicating HBV.
    MeSH term(s) Adult ; Female ; Hepatitis B/immunology ; Hepatitis B/transmission ; Hepatitis B/virology ; Hepatitis B Vaccines/immunology ; Hepatitis B Vaccines/therapeutic use ; Hepatitis B virus/drug effects ; Hepatitis B virus/immunology ; Hepatitis B virus/physiology ; Humans ; Infant, Newborn ; Infectious Disease Transmission, Vertical/prevention & control ; Pregnancy ; Pregnancy Complications, Infectious/immunology ; Pregnancy Complications, Infectious/prevention & control ; Pregnancy Complications, Infectious/virology
    Chemical Substances Hepatitis B Vaccines
    Language English
    Publishing date 2017-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1017370-5
    ISSN 1095-8320 ; 1045-1056
    ISSN (online) 1095-8320
    ISSN 1045-1056
    DOI 10.1016/j.biologicals.2017.08.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Book: VIRUS DISEASES OF THE LIVER

    Zuckerman, Arie J. / Taylor, Patricia E. / Sullman, Susan F.

    1970  

    Author's details A. J. ZUCKERMAN. WITH CONTRIB. BY PATRICIA E. TAYLOR AND SUSAN F. SULLMAN
    Language English
    Size X, 158 S. : ILL.
    Publisher BUTTERWORTH
    Publishing place LONDON
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT002585822
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  3. Journal ; Article ; Online: WHO collaborative evaluation of reference hepatitis B surface antigen and antibody reagents, subtype ad*

    Taylor, Patricia E.

    1975  

    Abstract: ... 283 ... ...

    Abstract 283

    292
    Keywords Viral Hepatitis
    Language English
    Document type Journal ; Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article: Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection.

    Nainan, Omana V / Khristova, Marina L / Byun, KwanSoo / Xia, Guoliang / Taylor, Patricia E / Stevens, Cladd E / Margolis, Harold S

    Journal of medical virology

    2002  Volume 68, Issue 3, Page(s) 319–327

    Abstract: Variants in the amino acid composition of the primary antibody-binding site of hepatitis B surface antigen (HBsAg) have been identified in a number of populations with chronic hepatitis B virus (HBV) infection. Direct sequencing of amplified or cloned ... ...

    Abstract Variants in the amino acid composition of the primary antibody-binding site of hepatitis B surface antigen (HBsAg) have been identified in a number of populations with chronic hepatitis B virus (HBV) infection. Direct sequencing of amplified or cloned PCR products, solid phase detection of sequence-specific PCR products (SP-PCR), and limiting dilution cloning PCR (LDC-PCR) were compared to determine their sensitivity in detecting differing concentrations of HBsAg variants. LDC-PCR had the greatest sensitivity and could detect HBsAg variants at a concentration of 0.1% of the total viral population. HBsAg variants were detected in 51% of infants with chronic HBV infection acquired after postexposure prophylaxis, and more than half of the variants were detected only by the most sensitive methods.
    MeSH term(s) Cloning, Molecular ; DNA, Viral/analysis ; Female ; Genetic Variation ; Hepatitis B Surface Antigens/blood ; Hepatitis B Surface Antigens/genetics ; Hepatitis B Vaccines/administration & dosage ; Hepatitis B virus/classification ; Hepatitis B virus/genetics ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/epidemiology ; Hepatitis B, Chronic/prevention & control ; Hepatitis B, Chronic/virology ; Humans ; Immunoglobulins/administration & dosage ; Infant ; Infant, Newborn ; Mutation ; Polymerase Chain Reaction/methods ; Pregnancy ; Pregnancy Complications, Infectious/therapy ; Retrospective Studies ; Sensitivity and Specificity ; Sequence Analysis, DNA
    Chemical Substances DNA, Viral ; Hepatitis B Surface Antigens ; Hepatitis B Vaccines ; Immunoglobulins ; hepatitis B hyperimmune globulin (XII270YC6M)
    Language English
    Publishing date 2002-11
    Publishing country United States
    Document type Comparative Study ; Journal Article
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.10206
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Hepatitis B Vaccine: Issues, Recommendations, and New Developments

    Stevens, Cladd E. / Taylor, Patricia E.

    Seminars in Liver Disease

    1986  Volume 6, Issue 01, Page(s) 23–27

    Language English
    Publishing date 1986-02-01
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 603177-8
    ISSN 1098-8971 ; 0272-8087
    ISSN (online) 1098-8971
    ISSN 0272-8087
    DOI 10.1055/s-2008-1040789
    Database Thieme publisher's database

    More links

    Kategorien

  6. Article: Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance.

    Gleaves, Curt A / Welle, John / Campbell, Mary / Elbeik, Tarek / Ng, Valerie / Taylor, Patricia E / Kuramoto, Ken / Aceituno, Sherri / Lewalski, Eva / Joppa, Barbara / Sawyer, Lynette / Schaper, Carl / McNairn, Denise / Quinn, Thomas

    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

    2002  Volume 25, Issue 2, Page(s) 205–216

    Abstract: Background: The use of quantitative HIV-1 RNA assays is part of the standard of care for the management of HIV-1-infected individuals.: Objective: The Bayer VERSANT HIV-1 RNA 3.0 Assay (bDNA) was evaluated for reproducibility, linearity, limits of ... ...

    Abstract Background: The use of quantitative HIV-1 RNA assays is part of the standard of care for the management of HIV-1-infected individuals.
    Objective: The Bayer VERSANT HIV-1 RNA 3.0 Assay (bDNA) was evaluated for reproducibility, linearity, limits of detection and quantitation, effects of potentially interfering substances and conditions, effects of plasma collection and handling conditions, clinical sensitivity and specificity, and biologic variability.
    Study design: Anti-HIV-1-positive specimens, patient specimens containing potentially interfering substances, and anti-HIV-negative specimens were collected from several HIV clinics, blood centers, or commercial companies across the United States. Specimen panels used to evaluate nonclinical performance of the assay were prepared at Bayer Diagnostics. Bayer Assay Development personnel performed 2 of the nonclinical studies-effect of freeze-thaw cycles using 'spiked' HIV-1 RNA-positive samples and effect of other disease organisms. All other studies were conducted at 7 external sites. In some of the studies performed, specimens were tested in parallel with the Roche AMPLICOR HIV-1 MONITOR version 1.0 PCR Test.
    Results/conclusions: The results of these studies showed that the Bayer Assay has excellent reproducibility, a broad linear range (75-500,000 HIV-1 RNA copies/ml), throughput of 168 patient results per two-plate run in a 22-h period, and few limitations for use. Because this test is designed for use only in individuals who are known to be HIV-1-positive, the clinical specificity of 97.6% is adequate for its intended use. These characteristics make it an attractive method for general laboratory use of monitoring HIV-1-infected patients.
    MeSH term(s) Branched DNA Signal Amplification Assay/methods ; HIV Infections/diagnosis ; HIV Infections/virology ; HIV-1/genetics ; HIV-1/isolation & purification ; Humans ; RNA, Viral/blood ; Reagent Kits, Diagnostic ; Reproducibility of Results ; Sensitivity and Specificity
    Chemical Substances RNA, Viral ; Reagent Kits, Diagnostic
    Language English
    Publishing date 2002-10-04
    Publishing country Netherlands
    Document type Clinical Trial ; Journal Article ; Multicenter Study
    ZDB-ID 1446080-4
    ISSN 1873-5967 ; 1386-6532
    ISSN (online) 1873-5967
    ISSN 1386-6532
    DOI 10.1016/s1386-6532(02)00011-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Placental/umbilical cord blood for unrelated-donor bone marrow reconstitution: relevance of nucleated red blood cells.

    Stevens, Cladd E / Gladstone, Jessica / Taylor, Patricia E / Scaradavou, Andromachi / Migliaccio, Anna Rita / Visser, Jan / Dobrila, N Ludy / Carrier, Carmelita / Cabbad, Michael / Wernet, Peter / Kurtzberg, Joanne / Rubinstein, Pablo

    Blood

    2002  Volume 100, Issue 7, Page(s) 2662–2664

    Abstract: Placental/umbilical cord blood (PCB) is a source of hematopoietic stem cells for bone marrow reconstitution. Engraftment speed and survival are related to the total nucleated cell (TNC) dose of the graft. This study explored the possible influence on ... ...

    Abstract Placental/umbilical cord blood (PCB) is a source of hematopoietic stem cells for bone marrow reconstitution. Engraftment speed and survival are related to the total nucleated cell (TNC) dose of the graft. This study explored the possible influence on engraftment of nucleated red blood cells (NRBCs) in the graft. Automated hematology analyzers were used to enumerate TNCs. NRBCs were counted by visual examination or by using an automated analyzer. Hematopoietic progenitor cells were enumerated as either colony-forming cells or CD34(+) cells. Transplant centers reported on transplant outcome in 1112 patients given PCB grafts through September 2001. NRBCs correlated with progenitor cell numbers. Both white blood cell and NRBC dose were independently predictive of myeloid engraftment speed. Because NRBC dose predicted engraftment speed, inclusion of NRBCs in the TNC count does not reduce the effectiveness of the prefreezing TNC count as an index of the quality of a PCB unit as a graft. The correlation between the number of NRBCs and the number of hematopoietic progenitor cells probably reflects the involvement of early stem cells in erythroid responses.
    MeSH term(s) Bone Marrow Cells/cytology ; Bone Marrow Cells/physiology ; Cell Nucleus/ultrastructure ; Erythrocytes/physiology ; Erythrocytes/ultrastructure ; Ethnic Groups ; Female ; Fetal Blood/physiology ; Hematopoietic Stem Cells/cytology ; Hematopoietic Stem Cells/physiology ; Humans ; Infant, Newborn ; Leukocytes/cytology ; Leukocytes/physiology ; Male ; Placenta/physiology ; Pregnancy ; Stem Cell Transplantation ; United States
    Language English
    Publishing date 2002-09-16
    Publishing country United States
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.V100.7.2662
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Book: Virus diseases of the liver

    Zuckerman, Arie J / Sullman, Susan F / Taylor, Patricia E

    [by] A. J. Zuckerman with contributions by Patricia E. Taylor and Susan F. Sullman

    1970  

    MeSH term(s) Liver Diseases ; Virus Diseases
    Language English
    Size x, 158 p., illus.
    Publisher Appleton-Century-Crofts
    Publishing place New York
    Document type Book
    ISBN 9780407437005 ; 0407437002
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

  9. Article: Presence of Particles other than the Australia-SH Antigen in a Case of Chronic Active Hepatitis with Cirrhosis

    Zuckerman, A. J. / Taylor, Patricia E.

    Abstract: Examination of serum specimens from a patient with chronic active hepatitis proved negative to the Australia-SH antigen by immunodiffusion and by complement fixation. Because the sera were anticomplementary they were examined with the electron microscope, ...

    Abstract Examination of serum specimens from a patient with chronic active hepatitis proved negative to the Australia-SH antigen by immunodiffusion and by complement fixation. Because the sera were anticomplementary they were examined with the electron microscope, and virus-like structures similar to members of the coronavirus group were identified. The possible significance of this finding in human serum and its relation to mouse hepatitis virus are discussed. A sample of the serum pool containing the MS-1 agent was found negative when examined by immunodiffusion, complement fixation, and electron microscopy. The possible lack of immunological identity between infectious and serum hepatitis is discussed.
    Keywords covid19
    Publisher PMC
    Document type Article
    Database COVID19

    Kategorien

To top